GSK releases data from albiglutide clinical programme
GSK plans to use the data for global regulatory submissions for its investigational glucagon-like peptide-1 (GLP-1) receptor agonist albiglutide to treat type 2 diabetes in early 2013. The
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.
Omeclamox-Pak, a ten-day, triple combination oral therapy, is comprised of omeprazole delayed-release capsules (20mg), clarithromycin tablets (500mg) and amoxicillin capsules (500mg). Pernix president and chief executive officer Cooper
The orphan drug designation provides substantial potential benefits to the sponsor, including funding for certain clinical studies, study-design assistance, tax incentives and seven years of market exclusivity for